Ernexa Therapeutics Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 15, 2026. The filing was submitted by the registrant, a Delaware corporation headquartered at 1035 Cambridge Street, Suite 18A in Cambridge, Massachusetts.
The report indicates that the company made an investor presentation available to the public on the same day. The filing states that a copy of this presentation is attached as Exhibit 99.1 to the Form 8-K and is incorporated by reference. The company also noted that the presentation would be available on its investor relations website, https://investor.ernexatx.com.
The Form 8-K serves as a disclosure mechanism for the company to distribute material information regarding its business and operations to its shareholders and the investing public.
